The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A Phase II Trial of Tideglusib in Alzheimer's Disease
Abstract
BACKGROUND: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD). OBJECTIVE: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. METHODS: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 weeks. The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints. RESULTS: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries. There were no statistically significant differences between either active and placebo arms in the efficacy variables. However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients. Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency. Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial. However, given the non-linear dose response, especially in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“The clinical studies in patients with mild-to-moderate AD (NCT01350362, NCT00948259) or PSP (NCT01049399) patients treated with tideglusib were negative on the clinical outcomes [218]; however, a subgroup analysis of PSP patients showed reduced brain atrophy [219].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [218]
In the citing paper
“However, a phase 2 trial in mild to moderate AD did not demonstrate any reduction in rate of cognitive or functional decline as compared to placebo (Lovestone et al., 2015)”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Lovestone et al., 2015
In the citing paper
“Tideglusib, a small-molecule GSK3β inhibitor, failed to improve cognition in a phase 2 clinical study, and CSF levels of Aβ42, total tau, and pTau181 were not altered, resulting in failure of the trial [175,176].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [176]
In the citing paper
“In a larger phase II study, tideglusib treatment was associated with significant cognitive improvement and a reduction in CSF levels of β-secretase in a subgroup of patients with mild AD122. However, when the entire study cohort was analysed, tideglusib was found to be well tolerated but produced no significant improvements122.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [122]
In the citing paper
“Another GSK-3 inhibitor, tideglusib, did not meet phase 2 clinical endpoints in patients with mild and moderate AD.80”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [80]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,535
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441
Cited by
Sorted by citations
Items 301–400 of 556
Beyond microtubule regulation: the multifaceted roles of tau in neuronal function and dysfunction
Bakota, L., Tulva, K., Trushina, N. I., & Brandt, R. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03947-1 · Cited by 12
Jangid, K., Devi, B., Rani, P., Kumar, N., Kumar, V., & Kumar, V. (2024) · ChemistrySelect · doi:10.1002/slct.202400808 · Cited by 12
Góral, I., Wichur, T., Sługocka, E., Godyń, J., Szałaj, N., Zaręba, P., Głuch‐Lutwin, M., Mordyl, B., Panek, D., & Więckowska, A. (2024) · Molecules · doi:10.3390/molecules29112616 · Cited by 12
Rajasekar, V., Abdalla, M. M., Basbrain, M. S., Neelakantan, P., & Yiu, C. K. Y. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04150-7 · Cited by 12
Vantaggiato, C., Guarato, G., Brivio, F., Panzeri, E., Speltoni, B., Gumeni, S., Orso, G., Santorelli, F. M., & Bassi, M. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107836 · Cited by 12
Jankowska, A., Satała, G., Bojarski, A. J., Pawłowski, M., & Chłoń‐Rzepa, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200427100453 · Cited by 12
Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
Vyas, J., Raytthatha, N., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00023-6 · Cited by 13
Fernandez, R. J., & Johnson, F. B. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13692 · Cited by 12
Akula, S. M., Candido, S., Abrams, S. L., Steelman, L. S., Lertpiriyapong, K., Cocco, L., Ramazzotti, G., Ratti, S., Follo, M. Y., Martelli, A. M., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100672 · Cited by 12
Moolman, C., van der Sluis, R., Beteck, R. M., & Legoabe, L. J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104839 · Cited by 12
Lee, S. Y., Chae, M. K., Yoon, J. S., & Kim, C. Y. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.15.25 · Cited by 12
Adult orthodontics: perils and pitfalls.
McDonald, F., & Cobourne, M. T. (2007) · PubMed · Cited by 12
Xun, Q., Zhang, J., Li, Y.-P., Li, Y., Ma, Y., Chen, Z., Ding, L.-P., & Shi, X.-L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117236 · Cited by 11
Smail, S. W., Kheder, A. H., Mustafa, H. K., Abdulqadir, S. Z., Jalal, K. F., Yashooa, R. K., Ghayour, M. B., Abdolmaleki, A., & Shekha, M. S. (2025) · Neurological Research · doi:10.1080/01616412.2025.2520983 · Cited by 11
Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease
Kemna, R. E., Kueck, P. J., Honea, R. A., Clark, Z., Rekowski, M. J., Weidling, I. W., Mayfield, H. D., John, C. S., Burns, J. M., Wilkins, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70390 · Cited by 11
Regulatory Pathways Governing Odonto/Osteogenic Differentiation in Dental Pulp Stem Cells
Kornsuthisopon, C., Nowwarote, N., Srisuwan, T., Dissanayaka, W. L., & Osathanon, T. (2025) · International Endodontic Journal · doi:10.1111/iej.70069 · Cited by 11
Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach
Haut, F., Argyrousi, E. K., & Arancio, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010259 · Cited by 11
PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport
Tziortzouda, P., Steyaert, J., Scheveneels, W., Sicart, A., Dittlau, K. S., Correia, A. M. B., Burg, T., Pal, A., Hermann, A., Damme, P. V., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02689-y · Cited by 11
Wei, D., Zhu, X., Li, S., Liu, G., Wang, Y. K., Wang, W., Zhang, Q., & Jiang, S. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.055 · Cited by 11
RetractedTau immunotherapy in Alzheimer’s disease and progressive supranuclear palsy
Karimi, N., Catak, F. B., Arslan, E. O., Saghazadeh, A., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109445 · Cited by 11
Norambuena, A., Sagar, V. K., Wang, Z., Raut, P., Feng, Z., Wallrabe, H., Pardo, E., Kim, T., Alam, S. R., Hu, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14144 · Cited by 10
Rahmatkar, S. N., & Singh, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04776-x · Cited by 10
Tauopathies: Emerging discoveries on tau protein, with a special focus on Alzheimer's disease
Hattiholi, A., Hegde, H., & Shetty, S. K. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102536 · Cited by 11
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)
Joshi, S. V., Soujanya, D., Supriya, M. S., Yaddanapudi, V. M., & Nanduri, S. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2536003 · Cited by 10
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
García‐Arriaza, J., Marín, M. Q., Merchán‐Rubira, J., Mascaraque, S. M., Medina, M., Ávila, J., Hernández, F., & Estéban, M. (2020) · Vaccines · doi:10.3390/vaccines8010127 · Cited by 11
Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis
Piazzi, M., Bavelloni, A., Cenni, V., Faenza, I., & Blalock, W. L. (2021) · Cells · doi:10.3390/cells10113255 · Cited by 10
Xu, M., Lantz, M. J., Nichols, R. A., & Li, Q. X. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00537 · Cited by 10
Arafa, R. K., & Elghazawy, N. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-60733-7_11 · Cited by 10
Mizoguchi, T. (2024) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2024.01.003 · Cited by 9
Nozal, V., Fernández-Gómez, P., García‐Rubia, A., Martínez‐González, L., Cuevas, E. P., Carro, E., Palomo, V., & Martı́nez, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116626 · Cited by 9
Alzheimer's Disease and Vascular Dementia, Connecting and Differentiating Features
Hurła, M., Banaszek, N., Kozubski, W. P., & Dorszewska, J. (2024) · Current Alzheimer Research · doi:10.2174/0115672050319219240711103459 · Cited by 10
Joshi, B., Singh, D., Wasan, H., Sharma, U., & Reeta, K. H. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106349 · Cited by 9
Zheng, X., Tang, Y., Yang, Q., Wang, S., Chen, R., Tao, C., Zhang, P., Fan, B., Zhan, J., Tang, C., et al. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18025 · Cited by 10
Kammula, S. V., Tripathi, S., Wang, N., Dawson, V. L., Dawson, T. M., & Mao, X. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.20 · Cited by 9
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9
Molecular Pathways Governing the Termination of Liver Regeneration
de Haan, L. R., van Golen, R. F., & Heger, M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000955 · Cited by 10
Dynamics of microtubules and their associated proteins
Benarroch, E. E. (2016) · Neurology · doi:10.1212/wnl.0000000000002686 · Cited by 9
Focusing on oligomeric tau as a therapeutic target in Alzheimer’s disease and other tauopathies
Rayman, J. B. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2206561 · Cited by 11
Teaching An Old Drug New Tricks: Repositioning Strategies for Spinal Muscular atrophy
Hoolachan, J. M., Sutton, E. R., & Bowerman, M. (2019) · Future Neurology · doi:10.2217/fnl-2019-0006 · Cited by 10
Alzheimer’s Disease and Dementia
Lewis, P. A., & Spillane, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811069-0.00002-1 · Cited by 9
Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection
Hedrich, W. D., & Wang, H. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-02997-y · Cited by 9
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Xun, Q., Zhang, J., Feng, L., Ma, Y., Li, Y., & Shi, X. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2466846 · Cited by 8
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions
Mohapatra, T. K., Nayak, R. R., Ganeshpurkar, A., Tiwari, P. K., & Kumar, D. (2025) · Ibrain · doi:10.1002/ibra.12197 · Cited by 8
Liu, Y., Zhang, J., Tang, L., Yang, J., Hao, L., Lou, F., & Su, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04174-1 · Cited by 8
Advances of therapeutic strategies for Alzheimer’s disease
Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 9
Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases
Zhang, L., Sun, H., Chen, Y., Wei, M., Lee, J., Li, F., & Ling, D. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1696 · Cited by 8
Role of proline‐rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease
Kumar, R. K., Tiwari, V., & Dey, S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15569 · Cited by 9
Diabetic Endothelial Cell Glycogen Synthase Kinase 3β Activation Induces VCAM1 Ectodomain Shedding
Brishti, M. A., Raghavan, S., Lamar, K., Singh, U. P., Collier, D. M., & Leo, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814105 · Cited by 8
Xiao, Z. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/obzs8887 · Cited by 8
Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 9
Effects of Specific Inhibitors for CaMK1D on a Primary Neuron Model for Alzheimer’s Disease
Grant, P., Kumar, J., Kar, S., & Overduin, M. (2021) · Molecules · doi:10.3390/molecules26247669 · Cited by 8
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 8
Milestoning simulation of ligand dissociation from the glycogen synthase kinase 3β
Rathnayake, S., Narayan, B., Elber, R., & Wong, C. F. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26423 · Cited by 8
Wang, F., Feng, J., Yang, Y., Liu, J., Liu, M., Wang, Z., Pei, H., Wei, Y., & Li, H. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s175484 · Cited by 8
GSK-3 Inhibitors: From the Brain to the Retina and Back Again
Sánchez-Cruz, A., Martı́nez, A., de la Rosa, E. J., & Hernández‐Sánchez, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_72 · Cited by 8
Small Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Masand, V. H., Al‐Hussain, S. A., Masand, G. S., Samad, A., Gawali, R. G., Jadhav, S., & Zaki, M. E. A. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108324 · Cited by 7
Zhu, Y., Wei, Y., Ma, J., Chen, W., Shen, Z., & Qiu, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101730 · Cited by 7
Sabeel, Z., Wang, J., Dong, J., Liu, Y., Yu, C., & Zhao, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189324 · Cited by 9
Lei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Di, C., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 7
Tang, F., Wei, J., Wong, M.-L., & Lei, P. (2025) · Genomic psychiatry : · doi:10.61373/gp025i.0122 · Cited by 7
Cancer drugs with high repositioning potential for Alzheimer’s disease
Majeed, J., Sabbagh, M. N., Kang, M. H., Lawrence, J. J., Pruitt, K., Bacus, S. S., Reyna, E., Brown, M., & Decourt, B. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2296079 · Cited by 9
Li, S., & Bhalla, R. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04178-w · Cited by 8
Li, X., Ba, Z., Huang, J., Chen, J., Jiang, J., Huang, N., & Luo, Y. (2024) · Ibrain · doi:10.1002/ibra.12176 · Cited by 7
Yeh, S., Chung, M.-H., & Chen, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011280 · Cited by 7
Chau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-2414-6_20 · Cited by 7
Kim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
Dual GSK3β/SIRT1 modulators for Alzheimer’s: mechanisms, drug discovery and future perspectives
Kareem, A. I., Kapp, E., Joubert, J., & Zou, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1662241 · Cited by 6
Abduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 7
Cosgun, K. N., Jumaa, H., Robinson, M. E., Cheng, Z., Oulghazi, S., Kume, K., Arce, D. F., Agadzhanian, N., Kistner, K. M., Léveillé, E., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01093-z · Cited by 6
Gorina, Y. V., Komleva, Y. K., Lopatina, O. L., Chernykh, A. I., & Salmina, A. B. (2019) · Annals of Clinical and Experimental Neurology · doi:10.25692/acen.2019.4.5 · Cited by 6
3-Arylidene-2-oxindoles as GSK3β inhibitors and anti-thrombotic agents
Babkov, D. A., Николаевна, Б. Е., Сиротенко, В. С., Othman, E., Klochkov, V. G., Sosonyuk, S. E., Lozinskaya, N. A., & Спасов, А. А. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129283 · Cited by 6
Talukder, M. E. K., Akhter, S., Ahammad, F., Aktar, A., Islam, M. S., Laboni, A. A., Afroze, M., Khan, M., Uddin, M. J., & Rahman, M. M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37178 · Cited by 6
Pažický, S., Alder, A., Mertens, H. D. T., Svergun, D. I., Gilberger, T., & Löw, C. (2022) · Biochemical Journal · doi:10.1042/bcj20210829 · Cited by 6
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
Olsson, B., Schott, J. M., Blennow, K., & Zetterberg, H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341311 · Cited by 7
Nozal, V., García‐Rubia, A., Cuevas, E. P., Pérez, C., Tosat‐Bitrián, C., Bartolomé, F. B., Carro, E., Ramírez, D., Palomo, V., & Martı́nez, A. (2021) · Angewandte Chemie · doi:10.1002/ange.202106295 · Cited by 6
Kinase inhibition in Alzheimer’s disease
Bagheri, S., & Saboury, A. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00003-x · Cited by 6
Masuda, Y. M., Sakagami, H., Yokose, S., & Udagawa, N. (2020) · In Vivo · doi:10.21873/invivo.11877 · Cited by 6
Varma, T., Kamble, P., Rajkumar., R., & Garg, P. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11320-5 · Cited by 5
Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease
Tassinari, E., & Milelli, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00681c · Cited by 5
Liu, W., Wu, L., Zeng, X., Chen, H., Ning, X., Sun, X., Xuan, W.-Q., Hao, Y., Jia, H., Li, Z., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118389 · Cited by 5
Manni, E., Al‐kuraishy, H. M., Eisawy, R., Abdelaziz, A. M., & Batiha, G. E. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-026-02518-9 · Cited by 5
Low, B. S. H., & Asimaki, A. (2024) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10567-x · Cited by 5
Dasgupta, A., Kalidass, K., Farisha, S., Saha, R., Ghosh, S. T., & Ampasala, D. R. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2411524 · Cited by 5
New Insights Into Genetic Right Ventricular Cardiomyopathies
Garcia-Montero, M., Fanous, Y., Krahn, A. D., Davies, B., Cadrin‐Tourigny, J., & Roberts, J. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.02.020 · Cited by 5
Emmerich, T. D., & Hayes, J. M. (2023) · Pharmaceuticals · doi:10.3390/ph16050661 · Cited by 5
Novel therapeutic approaches for targeting Alzheimer’s disease
Khodakiya, A., Chaudhary, S., Chaudhary, A., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00020-0 · Cited by 5
Gottlieb, S., van der Vaart, A. D., Hassan, A., Bledsoe, D., Morgan, A., O'Rourke, B., Rogers, W. D., Wolstenholme, J. T., & Miles, M. F. (2025) · Addiction Biology · doi:10.1111/adb.70044 · Cited by 5
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 6
Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy
Zaki, M. O., Elsherbiny, D. A., Salama, M., & Azab, S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120267 · Cited by 6
Recent advances in small molecule stimulation of regeneration and repair
Silpa, L., Sim, R. R. Y., & Russell, A. J. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128601 · Cited by 5
A Novel Neuroprotection Target With Distinct Regulation in Stroke and Alzheimer’s Disease
Gamir-Morralla, A., López‐Menéndez, C., Medina, M., & Iglesias, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00007-7 · Cited by 5
Tsui, H., Zeng, Q., Chen, K., & Zhang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13815-6 · Cited by 5
Wauters, E., Sleegers, K., Cruts, M., & Broeckhoven, C. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00009-9 · Cited by 6
Chen, Y., Dong, H., 黄筱玲, Jiang, L., Jiang, Z., Li, L., Hu, J., & Chen, W.-H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117639 · Cited by 4
Efficacy of medications in controlling cognitive dysfunction in Alzheimer’s : a systematic review
de Andrade, S. M., Rodrigues, Í. S. M., Rosa, L. M. V., Taminato, R. L., & dos Santos, G. A. A. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0243 · Cited by 4
Advancing Alzheimer’s therapeutics via in silico strategies: Tideglusib based multi-target analogues
Gambhir, S., & Singh, M. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108685 · Cited by 4
Metadata
- Authors
- Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., León, T., & del Ser, T.
- Affiliations
- University of Oxford (GB)
- Fundació ACE (ES)
- Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- Inserm (FR)
- University of Turku (FI)
- Instituto de Salud Carlos III (ES)
- Clinical Department, Noscira SA, Madrid, Spain
- Medical Department, Noscira SA, Madrid, Spain
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-03-03
- Volume
- 45
- Issue
- 1
- Pages
- 75-88
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1522284801
- Cited by
- 536
- References
- 47
- Citations by year
- 2026: 44 · 2025: 67 · 2024: 59 · 2023: 46 · 2022: 38 · 2021: 59 · 2020: 61 · 2019: 31 · 2018: 46 · 2017: 39 · 2016: 31 · 2015: 14
- FWCI
- 32.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10053)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tideglusib, Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Thiadiazoles, Amyloid beta-Peptides, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
